Tectonic Therapeutic (TECX) Q1 2026 earnings summary

Executive summary

• Clinical-stage biotech focused on GPCR-targeted biologics, with lead candidates TX45 and TX2100 in Phase 2 and Phase 1a trials, respectively; TX45 APEX Phase 2 trial in PH-HFpEF nearing enrollment completion and ALPINE Phase 2 trial launched in PH-ILD.

• Initiated TX2100 Phase 1a trial in HHT, with four cohorts dosed; topline results expected by end of Q3 2026.

• No revenue generated; operations funded primarily through equity offerings and private placements.

• Net loss increased to $25.2 million for Q1 2026, up from $15.9 million in Q1 2025.

• Strengthened board with appointments of François Nader, M.D., as Chair and Jessica Chutter as independent director.

Financial highlights

• Cash and cash equivalents were $236.9 million as of March 31, 2026, down from $253.8 million at December 31, 2025.

• Research and development expenses rose 60% year-over-year to $20.9 million, driven by clinical trial costs and increased headcount.

• General and administrative expenses increased to $6.4 million from $5.3 million year-over-year, mainly due to higher stock-based compensation.

• Net loss per share was $1.34, compared to $0.93 in the prior year quarter.

• Net cash used in operating activities was $18.4 million, with minimal investing activity and $0.8 million net cash from financing.

Outlook and guidance

• Cash runway expected to extend into Q4 2028, supporting ongoing and planned clinical trials.

• Topline results for TX45 Phase 2 trial expected late Q4 2026 or early Q1 2027; TX2100 Phase 1a topline data expected by end of Q3 2026.

• TX2100 Phase 2 trial in HHT planned for early 2027.

• Anticipates continued increase in R&D and G&A expenses as clinical programs advance.

• Additional capital may be needed for future development.